The DPP8 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human cervical adenocarcinoma HeLa cell line, engineered to ablate expression of the DPP8 gene. This polyclonal format provides a heterogeneous loss-of-function model that circumvents clonal artifacts, enabling robust functional studies without single-cell derived biases. The gene disruption is achieved via CRISPR/Cas9-mediated gene editing, resulting in a mixed population of DPP8-null cells suitable for pooled analyses of signaling and phenotypic outcomes.
The HeLa cell line, originally isolated from a cervical adenocarcinoma biopsy, is one of the most extensively utilized models in cancer biology. These cells are HPV18-positive and exhibit inactivation of the tumor suppressors p53 and Rb by viral oncoproteins, which facilitates unchecked proliferation and altered apoptotic signaling. Their epithelial origin and widespread use in drug discovery, signal transduction, and cell death research make them a highly relevant host for interrogating pathways involving inflammation and oncogenic transformation.
DPP8 encodes a serine exopeptidase that cleaves N-terminal dipeptides from substrates with Pro or Ala at the P2 position, regulating the availability of bioactive peptides. Inflammatory signals such as Interferon-?? and TNF-??, along with pathogen- and damage-associated molecular patterns, transcriptionally regulate DPP8. The protein interacts with DPP9, NLRP1, and RIPK1, forming complexes that control inflammasome assembly. DPP8 deficiency disrupts the processing of substrates like CXCL10, relieving suppression of the NLRP1 inflammasome. This triggers ASC-dependent caspase-1 activation, leading to cleavage and secretion of the pro-inflammatory cytokines IL-1?? and IL-18, and subsequent Gasdermin D-mediated pyroptotic cell death. Additionally, loss of DPP8 sensitizes cells to RIPK1-dependent apoptosis and RIPK3/MLKL-driven necroptosis, positioning DPP8 at a convergence point of multiple programmed cell death modalities.
In the HeLa background, DPP8 knockout accentuates the cell line??s intrinsic defects in apoptosis regulation and its HPV-driven immortalized state. The combination of viral oncoprotein-mediated p53/Rb inactivation and unleashed NLRP1 inflammasome activity creates a unique platform to dissect crosstalk between oncogenic signaling and innate immune pathways. This model is particularly valuable for exploring how cervical cancer cells might evade cell death or modulate inflammatory microenvironments, providing insights into potential therapeutic vulnerabilities.
Researchers can employ these polyclonal knockout cells in a broad range of assays, including Western blotting and ELISA to quantify caspase-1 activation and IL-1??/IL-18 release, LDH release and cell viability assays to measure pyroptotic and necrotic cell death, flow cytometry for apoptosis and necroptosis markers, and co-immunoprecipitation to probe RIPK1 complex formation. The model is also suited for transcriptomic profiling by RNA-seq and drug-target validation studies of DPP8/DPP9 inhibitors. Key applications encompass inflammasome biology, pyroptosis mechanisms, immune cell activation, cancer therapy resistance, and functional genomics. For further details or to inquire about customized solutions, please contact Ascent Research.
